Market Access News | pharmaphorum

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

Justin Klee and Joshua Cohen, co-CEOs of Amylyx Pharma

Amylyx plummets as confirmatory trial of ALS drug fails

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putti

News

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese.

News

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, del

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

News

In fiery SOTU, Biden proclaims “We finally beat big pharma”

Just days after the US presidential race officially narrowed to a contest between President Joe Biden and former president Donald Trump, it’s no surprise that Biden’s State of the Union spe

Acadia pulls trials of pimavanserin after schizophrenia fail

Amylyx plummets as confirmatory trial of ALS drug fails

FDA clears Wegovy’s label to include heart health benefits

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

MindMed gets FDA breakthrough tag for LSD in anxiety

In fiery SOTU, Biden proclaims “We finally beat big pharma”

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks